Agios Pharmaceuticals, Inc. (AGIO) Financial Statements
Agios Pharmaceuticals, Inc. (AGIO) reported trailing twelve-month revenue of $98.3M (up 140.6% year on year) and net income of -$411.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$365.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AGIOAgios Pharmaceuticals, Inc.Follow AGIO — free
—
Price chart with a free account
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.03 | 0.07 | 0.06 | 0.07 | 0.04 | 0.09 | 0.12 | 0.01 | 0.03 | 0.04 | 0.05 | 0.10 | |
| Gross profit | — | — | — | — | — | 0.09 | 0.12 | 0.01 | 0.02 | 0.03 | 0.05 | 0.09 | |
| Research & development | 0.05 | 0.10 | 0.14 | 0.22 | 0.29 | 0.34 | 0.21 | 0.28 | 0.30 | 0.30 | 0.34 | 0.36 | |
| Operating income | -0.04 | -0.05 | -0.12 | -0.20 | -0.32 | -0.36 | -0.32 | -0.39 | -0.39 | -0.43 | -0.47 | -0.46 | |
| Pre-tax income | -0.04 | -0.05 | -0.12 | -0.20 | -0.31 | -0.35 | -0.30 | -0.23 | -0.35 | 0.72 | -0.41 | — | |
| Income tax | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | -0.00 | — | |
| Net income | -0.04 | -0.05 | -0.12 | -0.20 | -0.31 | -0.35 | -0.41 | -0.23 | -0.35 | 0.67 | -0.41 | -0.41 | |
| Diluted EPS ($) | -2.83 | -1.59 | -3.15 | -5.07 | -6.75 | -6.03 | -6.86 | -4.23 | -6.33 | 11.64 | -7.12 | -7.01 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | 0.055 | 0.056 | 0.058 | 0.058 | — |
USD billions · SEC XBRL
Agios Pharmaceuticals, Inc. — questions
- What is Agios Pharmaceuticals, Inc.'s revenue?
- $98.3M over the twelve months to 2026-06-30, up 140.6% year on year, from its 10-Q and 10-K filings.
- What is Agios Pharmaceuticals, Inc.'s net income?
- -$411.3M over the twelve months to 2026-06-30.
- What is Agios Pharmaceuticals, Inc.'s free cash flow?
- -$365.3M over the twelve months to 2026-06-30.
- What are Agios Pharmaceuticals, Inc.'s diluted earnings per share?
- $-7.01 over the twelve months to 2026-06-30.
Every figure on this page comes from Agios Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.